Literature DB >> 32755846

Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection.

Timotius Ivan Hariyanto1, Andree Kurniawan2.   

Abstract

Entities:  

Keywords:  COVID-19; Coronavirus disease 2019; Endocrine disease; Metabolic disease; Thyroid disease

Mesh:

Year:  2020        PMID: 32755846      PMCID: PMC7387272          DOI: 10.1016/j.dsx.2020.07.044

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


× No keyword cloud information.
Dear Editor, Coronavirus disease 2019 (COVID-19) has caused significant health burden across the world. Identification of factors contributing to severe disease is important to enable stratification of risk, optimize the reallocation of hospital resources, and guide public health recommendations and interventions. Unfortunately, until now, no study provides clear evidence regarding the link between thyroid disease and COVID-19. This article aims to explore the potential association between thyroid disease and the severity of COVID-19 infection. A search of the literature was conducted on Google scholar using the keywords “thyroid disease” OR “hyperthyroid” OR “hypothyroid” OR “clinical characteristics” OR “comorbidities” OR “risk factors” AND “coronavirus disease 2019” OR “COVID-19”, between 2019 and present time (July 18th, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of thyroid disease in COVID-19 patients with a clinically validated definition of “severe disease” were included in this meta-analysis. A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Dichotomous variables were calculated using the Mantel-Haenszel formula with fixed-effects models. We used the I2 statistic to assess the heterogeneity, value of <25%, 26–50%, and >50% considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as odds ratio (OR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical significance set at ≤0.05. A total of 17,200 records were obtained through systematic electronic searches and other ways. After screening titles, abstracts, and full texts, 8 studies [[1], [2], [3], [4], [5], [6], [7], [8]] with a total of 2169 COVID-19 patients were included in the meta-analysis. The essential characteristics of included studies are summarized in Table 1 , whilst the individual and pooled ORs for thyroid disease predicting severe COVID-19 is shown in Fig. 1 . Our pooled analysis showed a significant association of thyroid disease with severe COVID-19, with no relevant heterogeneity [OR 2.48 (95% CI 1.32–4.66), p = 0.005, I 2 = 0%, fixed-effect modelling].
Table 1

Characteristics of included studies.

StudySample sizeDesignSevere patients
Non-severe patients
n (%)Age (years)n (%)Age (years)
Almazeedi S et al. [1] 20201096Retrospective cohort42 (3.8%)55 (44–66)1054 (96.2%)37 (21–53)
Cao M et al. [2] 2020198Retrospective cohort19 (9.6%)63 (56–80)179 (90.4%)48 (33–64)
Liu J et al. [3] 202040Retrospective cohort13 (32.5%)59 (49–70)27 (67.5%)43 (31–55)
Shabrawishi M et al. [4] 2020150Case series16 (10.6%)49 (34–65)134 (89.4%)46 (30–61)
Siso-Almirall [5]. 2020322Case series56 (17.3%)68 (53–83)266 (82.7%)54 (46–71)
Wang Y et al. [6] 202055Retrospective cohort2 (3.6%)62 (62–64)53 (96.4%)49 (3–69)
Yan S et al. [7] 2020168Retrospective cohort36 (21.4%)61 (50.3–68)132 (78.6%)49 (34–60)
Zhang J et al. [8] 2020140Retrospective cohort58 (41.4%)64 (25–87)82 (58.6%)51.5 (26–78)
Fig. 1

Forest plot that demonstrates the association of thyroid disease with severe COVID-19 disease.

Characteristics of included studies. Forest plot that demonstrates the association of thyroid disease with severe COVID-19 disease. Based on a contrite meta-analysis of available data, thyroid disease seems to be associated with an enhanced risk of severe COVID-19 infection. Several reasons can be proposed to explain this result. First, thyroid hormones were important in the regulation of innate immune response [9]. Therefore, excess or deficiency of thyroid hormones levels observed in thyroid disease will lead to dysregulation of innate immune response. Meanwhile, innate immune response were thought to be contributed the most in the pathogenesis of COVID-19 as it is the front lines of body defense system to fight against SARS-CoV-2, the virus responsible for causing COVID-19 infection. Dysregulation of innate immune response as evidenced by higher levels of neutrophil, increased levels of CD14+ monocytes and macrophages, decreased levels of NK cells, and increased levels of complement was significantly associated with severe COVID-19 infections [10]. Second, increased levels of proinflammatory cytokines such as TNF-α and IL-6 was observed in patients with thyroid disease [11,12]. Increased levels of these cytokines were also observed in patients with severe COVID-19 and correlates to the development of severe outcomes [13]. Finally, some thyroid patients, especially subacute thyroiditis were taking corticosteroids as their medications [14]. On the other side, meta-analysis showed that corticosteroid treatment in COVID-19 patients was associated with higher mortality, longer length of hospital stay, and higher rate of bacterial infections [15]. Patients with thyroid disease should hence be advised to take extra precaution to minimize risk exposure to the virus. Physicians should be engaged in close monitoring of thyroid disease patients with suspected COVID-19, for timely detecting signs of disease progression. Finally, the presence of thyroid disease shall be regarded as an important factor in future risk stratification models for COVID-19.

Funding

None.

Declaration of competing interest

The authors declare no conflict of interest regarding this article.
  23 in total

1.  Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19: A case report.

Authors:  Pin-Hsu Liao; Yu-Cheng Cheng; Po-Yu Liu; I-Te Lee
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

Review 2.  Impact of COVID-19 on the thyroid gland: an update.

Authors:  Lorenzo Scappaticcio; Fabián Pitoia; Katherine Esposito; Arnoldo Piccardo; Pierpaolo Trimboli
Journal:  Rev Endocr Metab Disord       Date:  2020-11-25       Impact factor: 6.514

3.  Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection.

Authors:  Timotius Ivan Hariyanto; Andree Kurniawan
Journal:  Obes Med       Date:  2020-08-18

4.  Is there an association between hypothyroidism and COVID 19? : A preliminary report.

Authors:  Satvinder Singh Bakshi; Vinoth Kumar Kalidoss
Journal:  Wien Klin Wochenschr       Date:  2021-02-03       Impact factor: 1.704

5.  Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.

Authors:  Timotius I Hariyanto; Andree Kurniawan
Journal:  Nutr Metab Cardiovasc Dis       Date:  2021-02-27       Impact factor: 4.222

6.  The Role of Fever Clinics in the Strategic Triage of Suspected Cases of Imported COVID-19.

Authors:  Hui Jia; Yuele Chang; Long Zhao; Yunxia Li; Lei Chen; Qian Zhang; Xianzhi Lou; Chenwei Li; Shuyue Xia
Journal:  Int J Gen Med       Date:  2021-05-25

7.  Thyroid disease and covid-19 infection: Case series.

Authors:  Magdy Mohamed Allam; Hanaa Tarek El-Zawawy; Soha Magdy Ahmed; Mohamed Aly Abdelhamid
Journal:  Clin Case Rep       Date:  2021-06-17

Review 8.  Coronavirus Disease 2019 and the Thyroid - Progress and Perspectives.

Authors:  Hidefumi Inaba; Toru Aizawa
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

Review 9.  Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review.

Authors:  Luca Giovanella; Rosaria M Ruggeri; Petra Petranović Ovčariček; Alfredo Campenni; Giorgio Treglia; Desiree Deandreis
Journal:  Clin Transl Imaging       Date:  2021-03-11

10.  Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection.

Authors:  Timotius Ivan Hariyanto; Andree Kurniawan
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.